Clinical Trial · NCT03436342

Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma

Overview

Chemokine receptor CXCR4 was expressed in MM and lymphoma cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of MM and lymphoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and prognostic evaluation of MM and lymphoma.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Fang Li, M.D. (PRINCIPAL_INVESTIGATOR)

Fang Li, M.D. (CONTACT)

lifang@pumch.cn

86-10-69155502

Yaping Luo, M.D. (CONTACT)

luoyaping@live.com

86-10-69157033

ClinicalTrials.gov

NCT03436342

Drug / Compound

Pentixafor

Isotope(s):

Target(s):

CXCR4

Ligand Class: Peptides

Chelator: DOTA

Linker: 4-aminomethylbenzoic acid

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

breastfeeding
any medical condition that in the opinion of the investigator,may significantly interfere with study compliance.
known allergy against Pentixafor
pregnancy